Numinus Wellness Inc.

NUMI

CA67054W1032

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 14:44:41 2024-05-28 EDT			5-day change	1st Jan Change
0.065 ^CAD	-7.14%		-7.14%	-40.91%

05-07	Numinus Wellness to Focus on U.S. Operations as it Transitions Out of Canada	MT
05-07	Numinus Wellness Brief: Announces a strategic plan designed to streamline expenses and "Sharpen" focus on Higher-growth U.S. operations	MT

Numinus Wellness Inc. Announces Departure of Stacey Wallin as Chief Strategy Officer

November 25, 2021 at 06:08 pm

Numinus Wellness Inc. announced that Stacey Wallin, previous Chief Strategy Officer, is no longer with the Company.

Latest news about Numinus Wellness Inc.

Numinus Wellness to Focus on U.S. Operations as it Transitions Out of Canada	05-07	MT
Numinus Wellness Brief: Announces a strategic plan designed to streamline expenses and "Sharpen" focus on Higher-growth U.S. operations	05-07	MT
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	04-17	MT
Cybin Selects Numinus Wellness Inc.'s Cedar Clinical Research as clinical research site for Its Phase 3 Study of CYB003	04-17	CI
Transcript : Numinus Wellness Inc., Q2 2024 Earnings Call, Apr 15, 2024	04-15
Numinus Wellness Drops 25% as it Explores Options for its Canadian Operations; FQ2 Profit Falls	04-15	MT
Toronto Stocks Edge Lower; Parkland Shares Up After Rebuffing Call for Strategic Review	04-15	DJ
Numinus Wellness Exploring Options For Canadian Operations; Comes After It Posted QoQ Decrease in Q2 Revenue, Gross Profit	04-15	MT
Numinus Wellness Brief: Co Has decided to Explore Opportunities to "Redefine, divest and/or discontinue" its Canadian clinical operations	04-15	MT
Numinus Wellness Brief: Says To Focus on U.S. operations and Citing "Strategic Adjustments" in its Canadian Market Presence	04-15	MT
Numinus Wellness Posts QoQ Decrease in Q2 Revenue, Gross Profit	04-15	MT
An undisclosed buyer agreed to acquire Canadian clinical operations from Numinus Wellness Inc..	04-14	CI
Numinus Wellness Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-12	CI
PharmAla Biotech Signs Sale Agreement with Numinus Wellness	03-26	MT
Numinus Wellness Submits Clinical Trial Application to Health Canada	03-20	MT
Numinus Wellness Brief: Says Submitted Clinical Trial Application	03-20	MT
Numinus Wellness Inc. Submits Clinical Trial Application	03-20	CI
Numinus Wellness Names Interim Chief Financial Officer	03-12	MT
Numinus Wellness Inc. Announces Chief Financial Officer Changes	03-12	CI
Numinus Wellness Inc. Announces Board Changes	03-12	CI
Numinus Wellness Notes MindMed's "Positive" Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder	03-08	MT
Numinus Wellness Closes $6 Million Bought Deal Public Offering	02-16	MT
Numinus Wellness Corrects Its Own Statement Related To Holdings In Co-Investment Feeder Fund 3; Announced $6 Million Bought Deal Public Offering	02-01	MT
Numinus Wellness Agrees to Sell Holdings in Alto Neuroscience	02-01	MT
Transcript : Numinus Wellness Inc., Q1 2024 Earnings Call, Jan 15, 2024	01-15

Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the development and delivery of mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Company's segments include Clinical Research Operations, Canadian Clinic Network and US Clinic Network. Its Clinical Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Its Canadian Clinic Network segment includes wellness clinics based in Canada offering clinical services, including traditional therapy and counseling, ketamine-assisted therapies, mindfulness programs, and virtual psychotherapy. The US Clinic Network segment includes wellness clinics based in the United States that offers clinical services, such as psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management.

Sector

Biotechnology & Medical Research

Calendar

2024-05-31 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Numinus Wellness Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.065

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NUMINUS WELLNESS INC.	-40.91%	15.28M
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+36.61%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research